The effects of manual therapy and exercises on pain, muscle strength, joint health, functionality and quality of life in haemophilic arthropathy of the elbow joint: A randomized controlled pilot study

Haemophilia ◽  
2021 ◽  
Author(s):  
Ayse Merve Tat ◽  
Filiz Can ◽  
Necati Muhammed Tat ◽  
Hatice Ilgen Sasmaz ◽  
Ali Bulent Antmen



2016 ◽  
Vol 12 ◽  
pp. P426-P426
Author(s):  
Anita E. Saltmarche ◽  
Margaret A. Naeser ◽  
Kai Fai Ho ◽  
Michael R. Hamblin ◽  
Lew Lim


2015 ◽  
Vol 25 (1) ◽  
pp. 23-31 ◽  
Author(s):  
Yun-Ling Chen ◽  
Ay-Woan Pan ◽  
Ping-Chuan Hsiung ◽  
Lyinn Chung


2011 ◽  
Vol 23 (3) ◽  
pp. 307-312 ◽  
Author(s):  
Jittima Manonai ◽  
Thitima Harnsomboon ◽  
Sirirat Sarit-apirak ◽  
Rujira Wattanayingcharoenchai ◽  
Apichart Chittacharoen ◽  
...  


Author(s):  
Manal El-Hamamsy ◽  
Hesham Elwakil ◽  
Amr S. Saad ◽  
May A. Shawki

Statins have been reported to have a potential radiosensitizing effect that has not been evaluated in clinical trials. The aim of this study was to evaluate the efficacy and safety of simvastatin in addition to whole-brain radiation therapy (WBRT) in patients with brain metastases (BM). A prospective randomized, controlled, open-label pilot study was conducted on 50 Egyptian patients with BM who were randomly assigned to receive 30-Gy WBRT (control group: 25 patients) or 30 Gy WBRT + simvastatin 80 mg/day for the WBRT period (simvastatin group: 25 patients). The primary outcome was radiological response at 4 weeks after WBRT. Secondary outcomes were 1-year progression-free survival (PFS), 1-year overall survival (OS), and health-related quality of life (HRQL) that was assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and its brain module (BN-20), at baseline, after WBRT, and 4 weeks after WBRT. The addition of simvastatin was tolerated. Twenty-one patients were not evaluated for radiological response because of death (n = 16), noncompliance to follow-up (n = 4), and clinical deterioration (n = 1). Response rates were 60% and 78.6% (p = 0.427), 1-year PFS rates were 5.2% and 17.7% (p = 0.392), and 1-year OS rates were 12% and 8% (p = 0.880) for the control group and simvastatin group, respectively. Nonsignificant differences were found between the two arms regarding HRQL scales. The addition of simvastatin 80 mg/day did not improve the clinical outcomes of patients with BM receiving WBRT.





Sign in / Sign up

Export Citation Format

Share Document